Compare DOMO & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOMO | CADL |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.7M | 1.0B |
| IPO Year | 2018 | 2021 |
| Metric | DOMO | CADL |
|---|---|---|
| Price | $3.91 | $10.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $10.28 | ★ $19.00 |
| AVG Volume (30 Days) | 1.1M | ★ 1.3M |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.92 | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $318,857,000.00 | $125,000.00 |
| Revenue This Year | $3.41 | N/A |
| Revenue Next Year | $4.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.84 | $4.35 |
| 52 Week High | $18.49 | $14.00 |
| Indicator | DOMO | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 54.45 | 35.42 |
| Support Level | $3.62 | $9.18 |
| Resistance Level | $4.05 | $10.59 |
| Average True Range (ATR) | 0.15 | 0.70 |
| MACD | -0.01 | -0.41 |
| Stochastic Oscillator | 59.26 | 11.22 |
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.